Antibacterial protein having lytic activity to Bacillus genus and method for preparing the same

Patent metadata

Field	Value
Publication number	US-12358953-B2
Application number	US-202117908853-A
Country	US
Kind code	B2
Filing date	Mar 6, 2021
Priority date	Mar 9, 2020
Publication date	Jul 15, 2025
Grant date	Jul 15, 2025

Abstract

An antibacterial protein against Bacillus with the amino acid sequence as set forth in SEQ ID NO: 1 is disclosed. Also disclosed is a method of preparing an antibacterial protein against Bacillus . The method includes: culturing BL21-pBAD-BAL200 cells, the BL21-pBAD-BAL200 cells including a plasmid that comprising a sequence as set forth in SEQ ID NO: 2; inducing the expression of the antibacterial protein; and purifying the antibacterial protein.

First claim

What is claimed is:

1. An antibacterial protein against Bacillus comprising the amino acid sequence of SEQ ID NO: 1.

2. The antibacterial protein of claim 1 , wherein the antibacterial protein consists of the amino acid sequence of SEQ ID NO: 1.

3. The antibacterial protein of claim 1 , wherein the antibacterial protein has lytic activity against Bacillus.

4. The antibacterial protein of claim 3 , wherein the antibacterial protein has lytic activity against Bacillus anthracis, Bacillus cereus, Bacillus circulans, Bacillus laevolacticus, Bacillus licheniformis, Bacillus megaterium , and Bacillus pumilus.

5. The antibacterial protein of claim 1 , wherein the antibacterial protein has no lytic activity against Salmonella, Escherichia coli ( E. coli ), Enterococcus faecalis , and Staphylococcus aureus.

6. A pharmaceutical composition for treating disease caused by Bacillus infection comprising the antibacterial protein of claim 1 .

7. The pharmaceutical composition of claim 6 , wherein the disease caused by Bacillus infection is selected from the group consisting of anthrax, food poisoning, bacteremia, septicemia, toxemia and cerebromeningitis.

8. The pharmaceutical composition of claim 6 , wherein the antibacterial protein is presented at a concentration of 0.1-50 mg/mL.

9. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition further comprises 10 mM L-Histidine.

10. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is used as food additives, antibiotics, disinfectants, and germicides.

11. A method of preparing the antibacterial protein of claim 1 , wherein the method comprises:
(a) culturing BL21-pBAD-BAL200 cells, wherein the BL21-pBAD-BAL200 cells comprise a plasmid comprising the nucleic acid sequence of SEQ ID NO: 2;
(b) inducing the expression of the antibacterial protein; and
(c) purifying the antibacterial protein.

12. The method of claim 11 , wherein the antibacterial protein has a purity of at least 90%.

Assignees

• Intron Biotechnology Inc

Inventors

• Yoon Seong Jun
• Jun Soo Youn
• Jung Gi Mo
• Lee Jin Hee
• Kang Sang Hyeon

Classifications

• A61K9/2045

  Polyamides; Polyaminoacids, e.g. polylysine · CPC title

• A61K9/2018

  Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N15/70

  Vectors or expression systems specially adapted for E. coli · CPC title